Belpointe Asset Management’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-25,588
Closed -$1.61M 1131
2026
Q1
$1.61M Buy
25,588
+20,685
+422% +$1.65M 0.06% 299
2025
Q4
$468K Sell
4,903
-3,640
-43% -$357K 0.02% 675
2025
Q3
$834K Buy
8,543
+3,495
+69% +$362K 0.03% 471
2025
Q2
$542K Buy
5,048
+2,747
+119% +$278K 0.02% 550
2025
Q1
$232K Sell
2,301
-5,305
-70% -$534K 0.01% 804
2024
Q4
$622K Sell
7,606
-746
-9% -$65.7K 0.04% 456
2024
Q3
$700K Buy
+8,352
New +$658K 0.04% 407
2024
Q2
Sell
-4,485
Closed -$307K 859
2024
Q1
$307K Buy
+4,485
New +$288K 0.02% 581
2023
Q2
Sell
-6,357
Closed -$318K 953
2023
Q1
$318K Buy
6,357
+627
+11% +$29.6K 0.02% 721
2022
Q4
$265K Buy
5,730
+457
+9% +$19.8K 0.02% 766
2022
Q3
$204K Buy
5,273
+1,965
+59% +$78.8K 0.01% 829
2022
Q2
$123K Sell
3,308
-764
-19% -$31.1K 0.01% 1020
2022
Q1
$181K Sell
4,072
-3,211
-44% -$139K 0.01% 953
2021
Q4
$309K Sell
7,283
-84
-1% -$3.53K 0.02% 694
2021
Q3
$320K Sell
7,367
-104
-1% -$4.6K 0.02% 658
2021
Q2
$319K Buy
+7,471
New +$314K 0.02% 650

Other funds holding BSX

Belpointe Asset Management's BSX Position: Q2 2026 in Review

Belpointe Asset Management sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 25,588 shares — an estimated $1.61M sold.

Belpointe Asset Management first reported a position in BSX in Q2 2021 and held it in 16 quarters. The position peaked at $1.61M in Q1 2026. 534 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Belpointe Asset Management reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
  • Belpointe Asset Management sold 25,588 Boston Scientific shares in Q2 2026, an estimated $1.61M.
  • Belpointe Asset Management first reported a position in Boston Scientific in Q2 2021 and held it in 16 quarters.
  • Belpointe Asset Management's Boston Scientific position peaked at $1.61M in Q1 2026.
  • 534 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.